Creative Planning raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 21.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,424 shares of the medical research company's stock after buying an additional 247 shares during the quarter. Creative Planning's holdings in Bio-Rad Laboratories were worth $594,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the business. Veritas Asset Management LLP bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $379,547,000. Millennium Management LLC grew its holdings in Bio-Rad Laboratories by 19.3% during the second quarter. Millennium Management LLC now owns 379,329 shares of the medical research company's stock worth $187,768,000 after buying an additional 61,424 shares in the last quarter. Prudential Financial Inc. grew its holdings in Bio-Rad Laboratories by 181.0% during the first quarter. Prudential Financial Inc. now owns 85,053 shares of the medical research company's stock worth $47,905,000 after buying an additional 54,789 shares in the last quarter. Brown Advisory Inc. grew its holdings in Bio-Rad Laboratories by 8.2% during the second quarter. Brown Advisory Inc. now owns 629,845 shares of the medical research company's stock worth $314,245,000 after buying an additional 47,921 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in Bio-Rad Laboratories by 11.3% during the first quarter. Invesco Ltd. now owns 352,100 shares of the medical research company's stock worth $198,311,000 after buying an additional 35,635 shares in the last quarter. 64.35% of the stock is owned by institutional investors and hedge funds.
Get Bio-Rad Laboratories alerts:Bio-Rad Laboratories Trading Up 1.3 %
Shares of BIO opened at $473.42 on Thursday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $344.63 and a fifty-two week high of $670.61. The business has a 50-day moving average of $429.97 and a 200 day moving average of $447.17. The firm has a market cap of $14.12 billion, a P/E ratio of -2.35 and a beta of 0.91. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.30 and a current ratio of 5.50.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on BIO shares. TheStreet downgraded Bio-Rad Laboratories from a "c" rating to a "d+" rating in a report on Thursday, October 27th. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, January 18th. Royal Bank of Canada started coverage on Bio-Rad Laboratories in a research note on Tuesday, December 6th. They issued an "outperform" rating and a $565.00 price objective for the company. Finally, Credit Suisse Group reduced their price objective on Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating for the company in a research note on Friday, October 28th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $651.25.Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
See Also
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.